236 related articles for article (PubMed ID: 31599769)
1. Malignant pheochromocytoma and paraganglioma: management options.
Corssmit EPM; Snel M; Kapiteijn E
Curr Opin Oncol; 2020 Jan; 32(1):20-26. PubMed ID: 31599769
[TBL] [Abstract][Full Text] [Related]
2. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma.
Ilanchezhian M; Jha A; Pacak K; Del Rivero J
Curr Treat Options Oncol; 2020 Aug; 21(11):85. PubMed ID: 32862332
[TBL] [Abstract][Full Text] [Related]
3. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management.
Hamidi O
Curr Opin Endocrinol Diabetes Obes; 2019 Jun; 26(3):146-154. PubMed ID: 30893083
[TBL] [Abstract][Full Text] [Related]
4. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies.
Jasim S; Jimenez C
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101354. PubMed ID: 31685417
[TBL] [Abstract][Full Text] [Related]
5. Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials.
Roman-Gonzalez A; Jimenez C
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):174-183. PubMed ID: 28234804
[TBL] [Abstract][Full Text] [Related]
6. Genomic Landscape of Pheochromocytoma and Paraganglioma.
Jochmanova I; Pacak K
Trends Cancer; 2018 Jan; 4(1):6-9. PubMed ID: 29413423
[TBL] [Abstract][Full Text] [Related]
7. Malignant pheochromocytoma and paraganglioma: three cases illustrating the use of molecular targeted diagnostics and therapy and possible role of new drugs.
Zukauskaite R; Hjorthgau K; Poulsen PL; Baerentzen S; Ladekarl M
Acta Oncol; 2011 Nov; 50(8):1255-9. PubMed ID: 21714698
[No Abstract] [Full Text] [Related]
8. The diagnosis and management of malignant phaeochromocytoma and paraganglioma.
Chrisoulidou A; Kaltsas G; Ilias I; Grossman AB
Endocr Relat Cancer; 2007 Sep; 14(3):569-85. PubMed ID: 17914089
[TBL] [Abstract][Full Text] [Related]
9. The management of benign and malignant pheochromocytoma and abdominal paraganglioma.
Edström Elder E; Hjelm Skog AL; Höög A; Hamberger B
Eur J Surg Oncol; 2003 Apr; 29(3):278-83. PubMed ID: 12657240
[TBL] [Abstract][Full Text] [Related]
10. Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.
Björklund P; Pacak K; Crona J
J Intern Med; 2016 Dec; 280(6):559-573. PubMed ID: 27165774
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Phaeochromocytoma: Spinning Towards More Promising Treatment Options.
Nölting S; Grossman A; Pacak K
Exp Clin Endocrinol Diabetes; 2019 Feb; 127(2-03):117-128. PubMed ID: 30235495
[TBL] [Abstract][Full Text] [Related]
12. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics.
Plouin PF; Fitzgerald P; Rich T; Ayala-Ramirez M; Perrier ND; Baudin E; Jimenez C
Horm Metab Res; 2012 May; 44(5):390-9. PubMed ID: 22314389
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in the management of pheochromocytoma and paraganglioma.
Tanabe A; Naruse M
Hypertens Res; 2020 Nov; 43(11):1141-1151. PubMed ID: 32778780
[TBL] [Abstract][Full Text] [Related]
14. Metastatic pheochromocytoma and paraganglioma.
Angelousi A; Kassi E; Zografos G; Kaltsas G
Eur J Clin Invest; 2015 Sep; 45(9):986-97. PubMed ID: 26183460
[TBL] [Abstract][Full Text] [Related]
15. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Nastos K; Cheung VTF; Toumpanakis C; Navalkissoor S; Quigley AM; Caplin M; Khoo B
J Surg Oncol; 2017 Mar; 115(4):425-434. PubMed ID: 28166370
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and management of metastatic pheochromocytoma and paraganglioma].
Jochmanová I; Lazúrová I
Vnitr Lek; 2017; 63(9):580-588. PubMed ID: 29120654
[TBL] [Abstract][Full Text] [Related]
17. Pheochromocytoma and paraganglioma.
Meyer-Rochow GY; Sidhu SB
Cancer Treat Res; 2010; 153():135-62. PubMed ID: 19957224
[No Abstract] [Full Text] [Related]
18. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
Taïeb D; Jha A; Treglia G; Pacak K
Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
[TBL] [Abstract][Full Text] [Related]
19. Primary malignant tumors of the adrenal glands.
Almeida MQ; Bezerra-Neto JE; Mendonça BB; Latronico AC; Fragoso MCBV
Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e756s. PubMed ID: 30540124
[TBL] [Abstract][Full Text] [Related]
20. 'Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis'.
Satapathy S; Mittal BR; Bhansali A
Clin Endocrinol (Oxf); 2019 Dec; 91(6):718-727. PubMed ID: 31569282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
